Tesamorelin 10mg + Ipamorelin 10mg Bundle
Em Estoque e Pronto para Envio dos EUA
Frete GRÁTIS em todos os pedidos nos EUA
Checkout seguro via processador de pagamento criptografado
+2.9kApenas para Uso em Pesquisa
Estes produtos sao destinados exclusivamente a pesquisa laboratorial e nao se destinam ao uso medico. Nao sao aprovados pela FDA para diagnosticar, tratar, curar ou prevenir qualquer doenca. Ao adquirir, voce certifica que os produtos serao utilizados exclusivamente para pesquisa e nao para consumo humano ou animal.
Bundle / Blend Research
This product contains Tesamorelin + Ipamorelin. Select a tab below to view the full Gold Standard research profile for each component.
Visao Geral
Tesamorelin (TH9507) e um(a) sintetico(a) 44-aminoacido analog of endogenous GHRH with a peso molecular of 5135.9 Da. It foi desenvolvido(a) por Theratechnologies Inc. to overcome the inherent instability of native GHRH, que has a meia-vida of apenas 3–8 minutes due to rapido(a) cleavage by DPP-4. [1] [2]
Key Structural Feature: A trans-3-hexenoic acid group is anchored para o(a) N-terminal tyrosine (Tyr1), rendering o peptideo resistant to DPP-4 degradacao and extending the meia-vida to aproximadamente 26–38 minutes. C-terminal is amidated (-NH₂). [3]
Regulatory Status:
- FDA: Tesamorelin is the active ingredient of an FDA-approved pharmaceutical (Egrifta); that approval does not apply to this research-grade material. [4]
- EMA: Application withdrawn; not marketed no(a) EU. [6]
- WADA: Prohibited (S2 — Peptide Hormones, Growth Factors). [5]
Developer: Theratechnologies Inc. (Montreal, Canada) — originally designated TH9507.
Pharmacokinetic Highlights:
- Half-Life: ~26–38 min
- Pulsatility: Preserves natural pulsatile GH secretion (diferentemente de rhGH)
Mecanismo de Acao
1. Receptor Target — GHRH Receptor
Tesamorelin acts como um(a) specific agonist para o(a) GHRH receptor (GHRHr), a seven-transmembrane G protein-coupled receptor (GPCR) located on somatotroph cells no(a) anterior pituitary gland. Binding potency is comparable to endogenous GHRH. [7]
2. DPP-4 Resistance
The trans-3-hexenoic acid modification no(a) N-terminal Tyr1 acts como um(a) chemical shield against DPP-4 cleavage. Native GHRH is rapidamente degradado(a) (T½ ~5 min); Tesamorelin's modification extends stability to ~26–38 min. [3]
3. Sinalizacao a Jusante Cascade
Gₛ → Adenylyl Cyclase → cAMP → PKA → Ca²⁺ Influx → GH Exocytosis:
- Receptor ativacao desencadeia the Gₛα subunit
- Gₛα estimula adenylyl cyclase, converting ATP to cAMP
- Elevated cAMP ativa Protein Kinase A (PKA)
- PKA opens voltage-gated Ca²⁺ channels → calcium influx
- Ca²⁺ desencadeia exocytosis of pre-stored GH vesicles
- Simultaneamente, cAMP promove GH gene transcricao (new GH synthesis) [7]
🔑 Pulsatility Preserved: Diferentemente de exogenous rhGH (which creates constant supraphysiological levels), Tesamorelin estimula natural pulsatile GH release. The IGF-1 negativo(a) feedback loop remains intact, preventing runaway GH production. [8]
The product supplied here is for uso em pesquisa apenas independentemente de regulatory status of related formulations.
4. Selectivity
Tesamorelin is highly selective para o(a) GHRH receptor. It does not significantly alter TSH, LH, ACTH, or Prolactin levels. Diferentemente de GHRPs (e.g., Ipamorelin), it nao bind the ghrelin receptor. [9]
5. Receptor-Level Summary
Receptor-level: GHRH-receptor agonist at anterior-pituitary somatotrophs (cAMP/PKA signalling). [7]
6. Comparison with Related Molecules
| Compound | Structure | Key Difference |
|---|---|---|
| Endogenous GHRH | Native 44 aa | Rapidly degraded by DPP-4 (T½ ~5 min) |
| Tesamorelin | 44 aa + hexenoyl cap | DPP-4 resistant (T½ ~30 min); pulsatile GH |
| Sermorelin | 29 aa fragment | Shorter T½ (~5–10 min); menos potent |
| CJC-1295 + DAC | GHRH analog + DAC | Days-long T½; continuous “GH bleed” (not pulsatile) |
| Somatropin (rhGH) | Exogenous GH | Bypasses pituitary; suprime natural production |
7. Pharmacokinetics
| Parameter | Value |
|---|---|
| Half-Life (T½) | ~26–38 min |
| GH Pulsatility | Preserved (natural pulses, IGF-1 feedback intact) |
| Metabolism | Proteolytic cleavage; no formal human metabolismo studies |
| Animal T½ | 21–45 min (dogs) |
Aplicacoes de Pesquisa
Tesamorelin is the active ingredient of an FDA-approved pharmaceutical (Egrifta). That approval does not apply to this research-grade material. Published literature is listed under References.
Preclinical GH models: nerve-regeneration and muscle re-innervation endpoints reported. [14]
Caracteristicas Bioquimicas
| Propriedade | Valor |
|---|---|
| Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular Weight | 5135.9 Da |
| Synonyms | TH9507, Egrifta, Egrifta SV, Egrifta WR, Tesamorelin acetate, [hexenoyl-trans-3-Tyr1]hGRF(1-44)NH₂, Hex-hGRF |
| Cas Number | 218949-48-5 (free base); 901758-09-6 (acetate) |
| Sequence | hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH₂ (44 aa) |
| Pubchem Cid | 16137828 |
| Monoisotopic Mass | N/A |
| Polar Area | N/A |
| Complexity | N/A |
| X Log P | N/A |
| Heavy Atom Count | N/A |
| H Bond Donor Count | N/A |
| H Bond Acceptor Count | N/A |
| Rotatable Bond Count | N/A |
Identifiers
| Pubchem Cid | |
|---|---|
| Inchi Key | |
| Inchi | |
| Smiles Isomeric | |
| Smiles Canonical | |
| Iupac Name |
Resumo da Pesquisa Pre-clinica
Regulatory Context
Tesamorelin is the active ingredient of an FDA-approved pharmaceutical (Egrifta). That approval does not apply to this research-grade material. Published literature is listed under References.
Handling Safety
Handle with standard laboratory PPE. Consult the SDS.
TODOS OS ARTIGOS E INFORMAÇÕES SOBRE PRODUTOS FORNECIDOS NESTE SITE SÃO APENAS PARA FINS INFORMATIVOS E EDUCACIONAIS.
Autores e Atribuicao
✍️ Article Author
Dr. Steven K. Grinspoon
Steven K. Grinspoon, MD, is Professor of Medicine at Harvard Medical School and leads the Program in Nutritional Metabolism at Massachusetts General Hospital. He served como o(a) lead US investigator para o(a) Egrifta ensaios clinicos and his research spans visceral tecido adiposo, risco cardiovascular, and NAFLD in HIV-infected sujeitos de estudo. He is a named inventor no(a) NAFLD/NASH patent for Tesamorelin. Steven K. Grinspoon é referenciado(a) como um(a) dos(as) principais cientistas envolvidos(as) na pesquisa e desenvolvimento de Tesamorelin. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a Pure US Peptide e este(a) médico(a).
🎓 Scientific Journal Author
Dr. Julian Falutz
Julian Falutz, MD, is affiliated com o(a) Montreal General Hospital and McGill University Health Centre. He serves as lead author no(a) pivotal multicenter Phase 3 ensaios clinicos and pooled tolerability analyses que estabeleceu Tesamorelin's efficacy in reducing visceral tecido adiposo in HIV-infected sujeitos de estudo. His work was central para o(a) aprovacao da FDA of Egrifta. Julian Falutz é referenciado(a) como um(a) dos(as) principais cientistas envolvidos(as) na pesquisa e desenvolvimento de Tesamorelin. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a Pure US Peptide e este(a) médico(a).
🔬 Contributing Researcher
Dr. Takara L. Stanley
Takara L. Stanley, MD, is at Massachusetts General Hospital and Harvard Medical School. She has conducted extensive research no(a) metabolic profile of Tesamorelin sujeitos de estudo, incluindo liver enzymes, inflammatory markers, and GH pulsatility. Her landmark Lancet HIV trial (2019) demonstrated Tesamorelin previne hepatico(a) fibrose progression in NAFLD. Takara L. Stanley é referenciado(a) como um(a) dos(as) principais cientistas envolvidos(as) na pesquisa e desenvolvimento de Tesamorelin. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a Pure US Peptide e este(a) médico(a).
Citacoes Referenciadas
Falutz J, Allas S, Kotler D, et al. AIDS, 19(12), 1279-87, 2005.
PubMedFerdinandi ES, Brazeau P, High K, et al. Basic Clin Pharmacol Toxicol, 100(1), 49-58, 2007.
PubMedFalutz J, Allas S, Blot K, et al. N Engl J Med, 357(23), 2359-70, 2007.
PubMedFalutz J, Mamputu JC, Potvin D, et al. J Clin Endocrinol Metab, 95(9), 4291-304, 2010.
PubMedWang Y, Tomlinson B. Expert Opin Investig Drugs, 18(3), 303-10, 2009.
PubMedGrunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev compound Discov, 10(2), 95-6, 2011.
PubMedStanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. J Clin Endocrinol Metab, 96(1), 150-8, 2011.
PubMedDhillon S. Drugs, 71(8), 1071-91, 2011.
PubMedSpooner LM, Olin JL. Ann Pharmacother, 46(2), 240-7, 2012.
PubMedStanley TL, Falutz J, Marsolais C, et al. Clin Infect Dis, 54(11), 1642-51, 2012.
PubMedStanley TL, Fourman LT, Feldpausch MN, et al. Lancet HIV, 6(12), e821-e830, 2019.
PubMedAdrian S, Scherzinger A, Sanyal A, et al. J Frailty Aging, 8(3), 154-159, 2019.
PubMedBaker LD, Barsness SM, Borson S, et al. Arch Neurol, 69(11), 1420-9, 2012.
PubMedLopez J, Quan A, Budihardjo J, et al. Growth Hormone Improves Nerve Regeneration, Muscle Re-innervation, and Functional Outcomes After Chronic Denervation Injury. Sci Rep, 9(1), 3117, 2019.
PubMedGrinspoon SK, Fourman L, Stanley T, et al. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores: Subanalysis. Open Forum Infect Dis, 12(Suppl 1), 2025.
PubMedClemmons DR, Miller S, Mamputu JC. PLoS One, 12(6), e0179538, 2017.
PubMedMakimura H, Feldpausch MN, Rope AM, et al. J Clin Endocrinol Metab, 97(12), 4769-79, 2012.
PubMedFourman LT, Czerwonka N, Feldpausch MN, et al. AIDS, 31(16), 2253-9, 2017.
PubMedMangili A, Falutz J, Mamputu JC, et al. PLoS One, 10(10), e0140358, 2015.
PubMedLake JE, La K, Erlandson KM, et al. AIDS, 35(9), 1395-1402, 2021.
PubMedMakimura H, Murphy CA, Feldpausch MN, Grinspoon SK. J Clin Endocrinol Metab, 99(1), 338-343, 2014.
PubMedStanley TL, Feldpausch MN, Oh J, et al. JAMA, 312(4), 380-9, 2014.
PubMedEllis RJ, Vaida F, Hu K, et al. J Infect Dis, 231(5), 1230-1238, 2025.
PubMedFalutz J, Potvin D, Mamputu JC, et al. J Acquir Immune Defic Syndr, 53(3), 311-22, 2010.
PubMedArmazenamento e Manuseio
Summary
Liofilizado: 2–8°C refrigerado, protegido da luz. Não congele.
❄️ Liofilizado Powder Storage
Armazene o liofilizado a 2°C a 8°C (36–46°F), protegido da luz. Não congele.
📊 Documentacao de qualidade
Os certificados publicados informam a pureza por HPLC e as endotoxinas quando testadas. Os principais produtos de degradacao deste peptideo sao deamidated forms (β-Asp8-Tesamorelin) and oxidized forms (Met27-oxidized). Peso molecular: 5135.9 Da. This product is apenas para uso em pesquisa (RUO).
Aviso de Uso em Pesquisa
For Research Use Only (RUO). This product is intended solely for in-vitro research and laboratory experimentation. It is not a drug, food, cosmetic, or medical device and has not been approved by the FDA for any human or veterinary use. It must not be used for therapeutic, diagnostic, or any other non-research purpose. Pure US Peptide does not condone or encourage the use of this product for anything other than strictly defined research applications. Users assume full responsibility for compliance with all applicable regulations and guidelines.
Certificado de Analise
Published certificates come from third-party laboratories. If this listing's certificate is still pending, the card below says so.
Latest Lab Report
Compostos de Pesquisa Relacionados
Tesamorelin/Ipamorelin Blend 11mg/6mg
Tesamorelin
20mg
Tesamorelin
10mg